Update on Diclectin

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Update on Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that it has been advised by the UK's regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), that the marketing authorisation submission for Diclectin has not been approved.

Diclectin, a treatment for nausea and vomiting of pregnancy, was in-licensed from Duchesnay Inc. of Canada ("Duchesnay") for the UK in 2015 and for a further nine European territories in 2016. The total amount paid to Duchesnay for all territories was £1.5 million.

Whilst this is disappointing news, this will have no material impact on the Company's expected near-term results.

Certain information contained in this announcement constituted inside information (as defined by Article 7 of the Market Abuse Regulation) prior to the dissemination of this announcement.

For further information:

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.